Nimotuzumab: all 127 studies that test it
Page 1 of 2. Open to participants first (42), then studies with results posted, then the rest; newest registration first within each.
- Nimotuzumab Plus Radiotherapy in Elderly Patients With Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07821242Phase 2
- A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic CancerNot yet recruitingNCT07736612Phase 1/2
- Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual GlioblastomaNot yet recruitingNCT07707973Phase 2
- Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT07706985Phase 3
- Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell CarcinomaRecruitingNCT07601737Phase 2
- Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07535567Phase 2/3
- Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCCRecruitingNCT07457528Phase 2
- Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal MalignanciesNot yet recruitingNCT07446270Phase 2
- Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar CancerRecruitingNCT07353723Phase 2
- Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaRecruitingNCT07333274Phase 3
- Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT07312578Phase 2
- Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic CancerNot yet recruitingNCT07277452Phase 2
- A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell CarcinomaRecruitingNCT07105592Phase 1/2
- Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II TrialRecruitingNCT07070479Phase 2
- An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder CancerNot yet recruitingNCT07053735Phase 1
- Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT06988956Phase 2
- AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic CancerNot yet recruitingNCT06938503Phase 2
- TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal CarcinomaRecruitingNCT06912711Phase 2
- HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer PatientsRecruitingNCT06770452Phase 2
- Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic CancerRecruitingNCT06722911Phase 2
- Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06718205Phase 2
- Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaRecruitingNCT06509009Phase 2
- Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer PatientsRecruitingNCT06429839Phase 2
- SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic CancerNot yet recruitingNCT06422156Phase 2
- Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment FailureRecruitingNCT06413017Phase 2
- Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT06410651Phase 2
- Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic CancerNot yet recruitingNCT06409429Phase 2/3
- Nimotuzumab Plus AG in Pancreatic Cancer With Liver MetastasisRecruitingNCT06405685Phase 2
- Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II StudyRecruitingNCT06404840Phase 2
- Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic CancerRecruitingNCT06389760Phase 2
- A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical CarcinomaNot yet recruitingNCT06333821Phase 3
- GNT Induction Treatment in Locally Advanced NPCRecruitingNCT06026878Phase 3
- Nimotuzumab for EGFR-amplified Advanced Pan Solid TumorsRecruitingNCT06022276Not applicable
- Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction AdenocarcinomaRecruitingNCT05978050Phase 3
- Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal CancerRecruitingNCT05800054Not applicable
- Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant ChemotherapyRecruitingNCT05772208Phase 3
- Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal CarcinomaRecruitingNCT05717790Not applicable
- Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical CancerRecruitingNCT05606263Phase 2
- Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine NeoplasmsNot yet recruitingNCT05316480Phase 2
- Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After SurgeryNot yet recruitingNCT05024019Phase 2
- Chemoradiotherapy in Esophageal or Esophagogastric Junction CancerRecruitingNCT04821778Phase 3
- Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell CarcinomaNot yet recruitingNCT04678791Not applicable
- A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic CancerCompletedNCT02395016Phase 3Results posted
- A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06879691Phase 4
- Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical CarcinomaCompletedNCT06781073Phase 3
- HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingNCT06773130Phase 1/2
- Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the CervixActive, not recruitingNCT06771596Phase 2
- Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic CancerActive, not recruitingNCT06429904Phase 2
- Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal CancerWithdrawnNCT06343116Phase 3
- Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old AgeCompletedNCT06048913Phase 2
- Phase IIa Study of Nimotuzumab to Treat Colorectal CancerCompletedNCT05278728Phase 1/2
- Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.Status unknownNCT04882462Phase 2
- Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung CancerStatus unknownNCT04833205Phase 2
- Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in ChildrenStatus unknownNCT04532229Phase 3
- TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile CancerCompletedNCT04475016Phase 2
- A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell CarcinomaStatus unknownNCT04367909Phase 2
- Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal CarcinomaActive, not recruitingNCT04223024Phase 2
- A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal CancerCompletedNCT04207918Phase 2
- Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal CarcinomaStatus unknownNCT03915132Phase 2
- Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal CarcinomaStatus unknownNCT03837808Phase 3
- Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT03766178Phase 2
- Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT03708822Phase 2
- Nimotuzumab for Recurrent Nasopharyngeal CarcinomaStatus unknownNCT03666221Phase 2
- Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt CoursesActive, not recruitingNCT03620032Phase 2
- Phase II Umbrella Study Directed by Next Generation SequencingStatus unknownNCT03574402Phase 2
- By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPCStatus unknownNCT03557112Phase 2
- Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK CellsStatus unknownNCT03554889Phase 1
- Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical CancerStatus unknownNCT03469531Phase 2
- Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical CarcinomCompletedNCT03413579Phase 3
- Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric AdenocarcinomaStatus unknownNCT03400592Phase 2
- Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral GlioblastomaCompletedNCT03388372Phase 2
- Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal CarcinomaCompletedNCT03025958Phase 2
- Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung CancerCompletedNCT02947386Phase 1
- Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic CancerStatus unknownNCT02945267Phase 4
- Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal CarcinomaStatus unknownNCT02858206Phase 2
- Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical CancerStatus unknownNCT02705612Phase 2
- Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in ChildrenStatus unknownNCT02672241Phase 2
- Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Phase 3
- Nimotuzumab in Combination With Radiotherapy for Esophageal CancerCompletedNCT02591784Phase 2
- Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung CancerCompletedNCT02577341Phase 2
- Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung CancerStatus unknownNCT02549261Not applicable
- Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung CarcinomaWithdrawnNCT02428764Phase 2
- A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell CarcinomaStatus unknownNCT02409186Phase 3
- Pharmacokinetics Study of Nimotuzumab in Patients With Solid TumorsCompletedNCT02395068Phase 1
- Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric AdenocarcinomaCompletedNCT02370849Phase 2
- Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal CarcinomaStatus unknownNCT02293356Phase 4
- Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell CarcinomaWithdrawnNCT02272699Phase 2/3
- A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical CancerCompletedNCT02095119Phase 1/2
- Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of EsophagusWithdrawnNCT02041819Phase 2
- Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical CancerStatus unknownNCT02039791Phase 2
- Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal CarcinomaWithdrawnNCT02034968Phase 2
- Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal CarcinomaWithdrawnNCT02011594Phase 2
- Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.Status unknownNCT01993784Phase 1/2
- Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer PatientsStatus unknownNCT01939054Phase 2
- Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal CancerStatus unknownNCT01899118Phase 2
- Afatinib Plus Nimotuzumb for NSCLCStatus unknownNCT01861223Phase 1/2
- Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction CancerTerminatedNCT01813253Phase 3
- Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx CancerStatus unknownNCT01516996Phase 2
- Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung CancerCompletedNCT01498562Phase 2
- Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer: a Single, Non-control Clinical TrialCompletedNCT01463605Phase 2